Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 8/20 | 0.71 |
| ▸ | PDE4A | P27815 | 14/20 | 0.65 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.65 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6284020 | 1.00 | TNF (0.71) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6287556 | 1.00 | TNF (0.71) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6287593 | 0.91 | TNF (0.76) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6280398 | 0.91 | TNF (0.76) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4864210 | 0.91 | TNF (0.76) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7441945 | 0.90 | TNF (0.74) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7436772 | 0.89 | TNF (0.67) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7432935 | 0.89 | TNF (0.67) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4858327 | 0.88 | TNF (0.65) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6289245 | 0.88 | TNF (0.65) | TNFPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0800514-B1 | SUBSTITUTED IMIDES AS TNF INHIBITORS | CELGENE CORP (US) | 2006-08-23 | — | — | EP | claimed |
| US-6429221-B1 | INHIBITORS OF TUMOR NECROSIS FACTOR; USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, AND RETROVIRUS REPLICATION | CELGENE CORPORATION | 2002-08-06 | — | — | US | claimed |
| US-7438917-B2 | Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes | INSTITUT PASTEUR (FR) | 2008-10-21 | — | — | US | disclosed |
| US-7329761-B2 | Substituted imides | CELGENE CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-20060182769-A1 | Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes | INSTITUT PASTEUR (FR) | 2006-08-17 | — | — | US | disclosed |
| US-20050090516-A1 | Novel substituted imides | MULLER GEORGE W (US) | 2005-04-28 | — | — | US | disclosed |
| US-6844359-B2 | Substituted imides | CELGENE CORPORATION (US) | 2005-01-18 | — | — | US | disclosed |
| US-20020143027-A1 | Novel substituted imides | MULLER GEORGE W (US) | 2002-10-03 | — | — | US | disclosed |
| US-6429221-B1 | INHIBITORS OF TUMOR NECROSIS FACTOR; USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, AND RETROVIRUS REPLICATION | CELGENE CORPORATION | 2002-08-06 | — | — | US | disclosed |
| WO-1996020926-A9 | SUBSTITUTED IMIDES AS TNF INHIBITORS | — | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143027-A1 | Novel substituted imides | TNF, MIF, TNFRSF1A | TNF 1/4885PDE4A 4093/4885PDE4B 4323/4885 |
| US-20050090516-A1 | Novel substituted imides | TNF, MIF, TNFRSF1A | TNF 1/4885PDE4A 4100/4885PDE4B 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.